Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07428746 · ClinicalTrials.gov registry record · Phase 3

Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes

A Phase 3 study, sponsored by Emory University.

Not yet
Registry status
Phase 3
Development phase
20
Enrollment target

NCT07428746: Clinical Trial Phase 3 study, sponsored by Emory University.

NCT07428746 is a Phase 3 study that has not yet begun recruiting, run by Emory University. The registered enrollment target is 20 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07428746, a Phase 3 study, has not yet begun recruiting, sponsored by Emory University.

NOT YET RECRUITING
Registry status
Phase 3
Development phase
20 participants
Enrollment target

Study Summary

The goal of this study is to learn how GLP-1 receptor agonist therapy affects muscle and bone health in older females over age 65 with type 2 diabetes. The main question it aims to answer is whether or not 6 months of GLP-1 RA therapy affects muscle strength. Participants will: * Receive GLP-1 RA therapy as part of their routine clinical care * Complete muscle strength assessments (hand grip strength, Timed Up and Go test) * Provide blood samples for bone turnover markers * Undergo bone mineral density testing

Primary Outcome

Handgrip strength is a validated indicator of overall muscle strength and a core diagnostic component of sarcopenia. HGS will be assessed using a calibrated hydraulic hand dynamometer. Output is recorded in kilograms (kg) of force. Higher values indicate greater muscle strength

Interventions

  • DRUG Semaglutide

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2026-04
Est. Completion 2028-11
Phase Phase 3
Emory University

1,208 total trials

What is known before NCT07428746 opens enrollment

NCT07428746 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 1 intervention - of which Semaglutide is the first listed.

NCT07428746 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07428746 about?

NCT07428746 is a clinical study titled "Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes". The goal of this study is to learn how GLP-1 receptor agonist therapy affects muscle and bone health in older females over age 65 with type 2 diabetes. The main question it aims to answer is whether or not 6 months of GLP-1 RA therapy affects muscle strength. Participants will: * Receive GLP-1 RA...

What is the current status of trial NCT07428746?

This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2026-04. Estimated completion is 2028-11.

What interventions are being tested in trial NCT07428746?

The interventions under investigation include: Semaglutide (DRUG).

Who is sponsoring clinical trial NCT07428746?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07428746's enrollment target sits among peer trials

20 1956th of 2000 higher than 32 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT07428746, the US trial registry maintained by the National Library of Medicine. NCT07428746 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.